Cargando…
Recent advances in treating Parkinson’s disease
This article summarizes (1) the recent achievements to further improve symptomatic therapy of motor Parkinson’s disease (PD) symptoms, (2) the still-few attempts to systematically search for symptomatic therapy of non-motor symptoms in PD, and (3) the advances in the development and clinical testing...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000Research
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357034/ https://www.ncbi.nlm.nih.gov/pubmed/28357055 http://dx.doi.org/10.12688/f1000research.10100.1 |
_version_ | 1782515973109055488 |
---|---|
author | Oertel, Wolfgang H. |
author_facet | Oertel, Wolfgang H. |
author_sort | Oertel, Wolfgang H. |
collection | PubMed |
description | This article summarizes (1) the recent achievements to further improve symptomatic therapy of motor Parkinson’s disease (PD) symptoms, (2) the still-few attempts to systematically search for symptomatic therapy of non-motor symptoms in PD, and (3) the advances in the development and clinical testing of compounds which promise to offer disease modification in already-manifest PD. However, prevention (that is, slowing or stopping PD in a prodromal stage) is still a dream and one reason for this is that we have no consensus on primary endpoints for clinical trials which reflect the progression in prodromal stages of PD, such as in rapid eye movement sleep behavior disorder (RBD) —a methodological challenge to be met in the future. |
format | Online Article Text |
id | pubmed-5357034 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | F1000Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-53570342017-03-28 Recent advances in treating Parkinson’s disease Oertel, Wolfgang H. F1000Res Review This article summarizes (1) the recent achievements to further improve symptomatic therapy of motor Parkinson’s disease (PD) symptoms, (2) the still-few attempts to systematically search for symptomatic therapy of non-motor symptoms in PD, and (3) the advances in the development and clinical testing of compounds which promise to offer disease modification in already-manifest PD. However, prevention (that is, slowing or stopping PD in a prodromal stage) is still a dream and one reason for this is that we have no consensus on primary endpoints for clinical trials which reflect the progression in prodromal stages of PD, such as in rapid eye movement sleep behavior disorder (RBD) —a methodological challenge to be met in the future. F1000Research 2017-03-13 /pmc/articles/PMC5357034/ /pubmed/28357055 http://dx.doi.org/10.12688/f1000research.10100.1 Text en Copyright: © 2017 Oertel WH http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Oertel, Wolfgang H. Recent advances in treating Parkinson’s disease |
title | Recent advances in treating Parkinson’s disease |
title_full | Recent advances in treating Parkinson’s disease |
title_fullStr | Recent advances in treating Parkinson’s disease |
title_full_unstemmed | Recent advances in treating Parkinson’s disease |
title_short | Recent advances in treating Parkinson’s disease |
title_sort | recent advances in treating parkinson’s disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357034/ https://www.ncbi.nlm.nih.gov/pubmed/28357055 http://dx.doi.org/10.12688/f1000research.10100.1 |
work_keys_str_mv | AT oertelwolfgangh recentadvancesintreatingparkinsonsdisease |